| Fireweed Therapy Llc | |
|
2610 Mcrae Rd Unit A, Anchorage, AK 99517-2509 | |
| (907) 312-5344 | |
| Not Available |
| Full Name | Fireweed Therapy Llc |
|---|---|
| Type | Facility |
| Speciality | Occupational Therapist |
| Location | 2610 Mcrae Rd Unit A, Anchorage, Alaska |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922795277 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | (* (Not Available)) | Primary |
| Provider Name | Alaena Katherine Bateman |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1528698818 PECOS PAC ID: 7618332297 Enrollment ID: I20230504000493 |
News Archive
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
Cellectis S.A., the French genome engineering specialist, has announced that the European Patent Office has today upheld European Patent EP 1 485 475 owned by Cellectis and relating to the invention of engineering methods for meganucleases. This method is based on the genetic fusion of meganuclease modules to obtain hybrid meganucleases.
A group of genes whose expression is significantly altered following exposure to drug paraphernalia after an enforced 'cold-turkey' period have been identified. Researchers writing in the open access journal BMC Neuroscience studied gene expression in the brains of heroin-addicted rats, identifying those genes that may be involved in precipitating a relapse.
Researchers at UC Davis, Genentech and Foundation Medicine are the first to show that a blood-based test to assess tumor mutational burden accurately identifies non-small cell lung cancer (NSCLC) patients who could benefit from immunotherapies called checkpoint inhibitors.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fireweed Therapy Llc Po Box 876106, Wasilla, AK 99687-6106 Ph: (907) 312-5344 | Fireweed Therapy Llc 2610 Mcrae Rd Unit A, Anchorage, AK 99517-2509 Ph: (907) 312-5344 |
News Archive
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
Cellectis S.A., the French genome engineering specialist, has announced that the European Patent Office has today upheld European Patent EP 1 485 475 owned by Cellectis and relating to the invention of engineering methods for meganucleases. This method is based on the genetic fusion of meganuclease modules to obtain hybrid meganucleases.
A group of genes whose expression is significantly altered following exposure to drug paraphernalia after an enforced 'cold-turkey' period have been identified. Researchers writing in the open access journal BMC Neuroscience studied gene expression in the brains of heroin-addicted rats, identifying those genes that may be involved in precipitating a relapse.
Researchers at UC Davis, Genentech and Foundation Medicine are the first to show that a blood-based test to assess tumor mutational burden accurately identifies non-small cell lung cancer (NSCLC) patients who could benefit from immunotherapies called checkpoint inhibitors.
› Verified 4 days ago
Paige N Thorne, MOTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 3831 Piper St Ste 220, Anchorage, AK 99508 Phone: 760-936-9766 | |
Forget Me Not Ot Llc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1048 W International Airport Rd, Suite 103, Anchorage, AK 99518 Phone: 907-317-5545 Fax: 907-865-2499 | |
Eva Cress Lyons, OTD Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 3801 Lake Otis Pkwy, Anchorage, AK 99508 Phone: 907-562-2277 | |
Mrs. Stacey Marie Lord, OTR L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 8200 Homer Dr Ste F, Anchorage, AK 99518 Phone: 907-345-0050 Fax: 907-344-5103 | |
Ms. Tamara Dawn Moore, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 600 W 41st Ave Ste 103, Anchorage, AK 99503 Phone: 907-306-1728 Fax: 907-334-9320 | |
Marie Koleka Swanson, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 8200 Homer Dr Ste F, Anchorage, AK 99518 Phone: 907-345-0050 Fax: 907-344-5103 | |
Alexa Hanley, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 9100 Centennial Cir, Anchorage, AK 99504 Phone: 907-333-8100 |